Concomitant osimertinib and antituberculosis therapy in an elderly patient with EGFR-mutated lung cancer and pulmonary tuberculosis: A case report

被引：1

作者：

Matsuura, Hiroaki ^{[1
]}

Higo, Hisao ^{[1
]}

Kuribayashi, Tadahiro ^{[1
]}

Tamaoki, Akihiko ^{[2
]}

Nakasuka, Takamasa ^{[1
]}

Uno, Mari ^{[1
]}

Makimoto, Go ^{[1
]}

Ninomiya, Kiichiro ^{[1
]}

Fujii, Masanori ^{[1
]}

Rai, Kammei ^{[1
]}

Ichihara, Eiki ^{[1
]}

Hotta, Katsuyuki ^{[1
]}

Miyahara, Nobuaki ^{[1
]}

Tabata, Masahiro ^{[1
]}

Maeda, Yoshinobu ^{[3
]}

Kiura, Katsuyuki ^{[1
]}

Ohashi, Kadoaki ^{[1
]}

机构：

[1] Okayama Univ Hosp, cho Kita Ward, 2 5 1 Shikata cho Kita Ward, Okayama 7008558, Japan

[2] Okayama Hlth Fdn Hosp, Okayama Hlth Fdn, Okayama 7000952, Japan

[3] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Hematol Oncol & Resp Med, Okayama, Japan

来源：

THORACIC CANCER | 2024年 / 15卷 / 17期

关键词：

case report; EGFR-mutated lung cancer; osimertinib; pulmonary tuberculosis; rifampicin; GEFITINIB;

D O I：

10.1111/1759-7714.15324

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The concurrent incidence of lung cancer and tuberculosis is expected to escalate due to the projected growth in the older population. Combination therapy with osimertinib and antituberculosis drugs has not been well-established. We report a case of successful treatment involving the concomitant administration of osimertinib and antituberculosis drugs in an older patient, an 89-year-old female, diagnosed with epidermal growth factor receptor (EGFR)-mutant lung cancer and pulmonary tuberculosis. Accumulating evidence is warranted to develop an optimal treatment strategy for patients with lung cancer and tuberculosis.

引用

页码：1390 / 1394

页数：5

共 50 条

[41] Cardiac Adverse Events in EGFR-Mutated Non-Small Cell Lung Cancer Treated With Osimertinib
Kunimasa, Kei
Kamada, Risa
Oka, Toru
Oboshi, Makiko
Kimura, Madoka
Inoue, Takako
Tamiya, Motohiro
Nishikawa, Tatsuya
Yasui, Taku
Shioyama, Wataru
Nishino, Kazumi
Imamura, Fumio
Kumagai, Toru
Fujita, Masashi
JACC: CARDIOONCOLOGY, 2020, 2 (01): : 1 - 10
[42] Recurrence as a small cell lung cancer transformation in a resected stage IIIA EGFR-mutated non-small cell lung cancer treated with adjuvant osimertinib: a case report
Lasvergnas, Julie
Monnet, Isabelle
Auliac, Jean-Bernard
Rousseau-Bussac, Gaelle
Chouaid, Christos
Assie, Jean-Baptiste
TRANSLATIONAL LUNG CANCER RESEARCH, 2025, 14 (01) : 287 - 291
[43] Investigating osimertinib plus chemotherapy in EGFR-mutated advanced non-small cell lung cancer
Spagnuolo, Alessia
Gridelli, Cesare
EXPERT OPINION ON PHARMACOTHERAPY, 2025,
[44] Early dose reduction of osimertinib in advanced EGFR-mutated non-small cell lung cancer
Ferreira, Marion
Ebia, Matthew I.
Reckamp, Karen L.
ANTI-CANCER DRUGS, 2024, 35 (07) : 672 - 679
[45] Small cell lung cancer transformation from EGFR-mutated lung adenocarcinoma: A case report and literatures review
Liu, Yangyang
CANCER BIOLOGY & THERAPY, 2018, 19 (06) : 445 - 449
[46] Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
Kai Fu
Fachao Xie
Fang Wang
Liwu Fu
Journal of Hematology & Oncology, 15
[47] Treatment Response To Osimertinib In EGFR-Mutated Leptomeningeal Metastases From Non-Small Cell Lung Cancer: A Case Series
Li, Huiying
Yu, Tingting
Huang, Mingmin
Guo, Aibin
Qian, Xiaoping
Yin, Zhenyu
ONCOTARGETS AND THERAPY, 2019, 12 : 7785 - 7790
[48] Hepatic Rupture as the Initial Presentation of an EGFR-Mutated Lung Adenocarcinoma: A Case Report
Mirallas, Oriol
Bosch-Schips, Marc
Pardo, Nuria
Aubanell, Anton
Salcedo-Allende, Maria Teresa
Callejo, Ana
Iranzo, Patricia
Tabernero, Josep
Felip, Enriqueta
FRONTIERS IN ONCOLOGY, 2022, 12
[49] Small cell conversion complicated with hypertrophic pulmonary osteoarthropathy after targeted therapy for advanced EGFR-mutated lung adenocarcinoma: A case report
Zhang, Sijia
Chen, Leichong
Zhu, Kuikui
Meng, Rui
INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY, 2024, 67 (01) : 217 - 222
[50] Identification and in silico structural insights of rare recurrent EGFR mutations as resistance mechanisms to osimertinib in EGFR-mutated lung cancer.
Na Zhoutong
Wu, Changling
Lu, Binbin
Cao, Ran
Ma, Yutong
Bao, Hua
Ou, Qiuxiang
Wu, Xue
Shao, Yang
Wang, Zhaoxia
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)

← 1 2 3 4 5 →